Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of sefaxersen in primary IgA nephropathy at high risk of progression
2022-502102-32-00Phase 3Authorised
- Sponsor
- Roche
- Start
- Nov 2023
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial in IgA nephropathy (IgAN) comparing Sefaxersen with Placebo (2 arms). Primary endpoint: Change in proteinuria at Week 37. Planned start Nov 2023; status: authorised.
02
Drugs
sefaxersen
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on 2022-502102-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502102-32-00.